Design of a Phase III, Double-Blind, Randomised, Placebo-Controlled Trial of Bi 1015550 in Patients With Progressive Pulmonary Fibrosis (Fibroneer-Ild)

Authors

Toby M Maher
Shervin Assassi
Arata Azuma
Vincent Cottin
Anna-Maria Hoffmann-Vold
Michael Kreuter
Justin M Oldham
Luca Richeldi
Claudia Valenzuela
Marlies S Wijsenbeek
Carl Coeck
Christina Schlecker
Florian Voss
Daniel Wachtlin
Fernando J Martinez

Publication Date

9-1-2023

Journal

BMJ Open Respiratory Research

Abstract

INTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).

METHODS AND ANALYSIS: In this phase III, double-blind, placebo-controlled trial, patients are being randomised 1:1:1 to receive BI 1015550 (9 mg or 18 mg) or placebo twice daily over at least 52 weeks, stratified by background nintedanib use. Patients must be diagnosed with pulmonary fibrosis other than IPF that is progressive, based on predefined criteria. Patients must have forced vital capacity (FVC) ≥45% predicted and haemoglobin-corrected diffusing capacity of the lung for carbon monoxide ≥25% predicted. Patients must be receiving nintedanib for at least 12 weeks, or not receiving nintedanib for at least 8 weeks, prior to screening. Patients on stable treatment with permitted immunosuppressives (eg, methotrexate, azathioprine) may continue their treatment throughout the trial. Patients with clinically significant airway obstruction or other pulmonary abnormalities, and those using immunosuppressives that may confound FVC results (cyclophosphamide, tocilizumab, mycophenolate, rituximab) or high-dose steroids will be excluded. The primary endpoint is absolute change from baseline in FVC (mL) at week 52. The key secondary endpoint is time to the first occurrence of any acute ILD exacerbation, hospitalisation for respiratory cause or death, over the duration of the trial.

ETHICS AND DISSEMINATION: The trial is being carried out in accordance with the ethical principles of the Declaration of Helsinki, the International Council on Harmonisation Guideline for Good Clinical Practice and other local ethics committees. The study results will be disseminated at scientific congresses and in peer-reviewed publications.

TRIAL REGISTRATION NUMBER: NCT05321082.

Keywords

Humans, Idiopathic Pulmonary Fibrosis, Double-Blind Method, Immunosuppressive Agents, Patients

Comments

Supplementary Materials

PMID: 37709661